Navigation Links
Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
Date:10/23/2007

License with University of Pittsburgh Brings Additional Key Gene Locus as a

Development Opportunity for Recently-Funded Company

NEW HAVEN, Conn., Oct. 23 /PRNewswire/ -- Optherion, Inc., a company developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that it has licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on Chromosome 10.

Scientists at the University of Pittsburgh published in 2005 their findings of a link between Chromosome 10, specifically the LOC387715 and HTRA1 genes, and AMD, the leading cause of blindness in people over 60 in the developed world. Genetic tests that can identify people at risk of developing AMD, or that can predict the likely rate of progression and end-stage outcome of patients already diagnosed, should enable medical professionals to intervene more aggressively at an earlier stage with lifestyle changes and available therapies, thereby changing the course of disease.

AMD is caused by degeneration of the macula, the region of the retina responsible for central vision. AMD is unique in that it is a common disease that has recently been linked to common variations in only a few specific genes, presenting opportunities to develop both diagnostic tests and disease- modifying treatments. There are 15-20 million people with AMD in the U.S. and more than 50 million worldwide.

Optherion announced on October 9 that it had completed a $37 million financing. The Company was founded following scientific discoveries published in 2005 linking the role of Complement Factor H (CFH) and Complement Factor B (CFB) -- both regulators of the alternative complement pathway - to AMD. Three gene loci have been strongly linked to AMD: CFH, CFB, and specific variations on Chromosome 10. About half of patients with AMD suffer from variations in the CFH gene, while 74% of the disease can be explained by variations in the CFH and CFB genes combined. Variations associated with specific gene loci on Chromosome 10 in combination with CFH are associated with about 79% of the disease.

Colin J. Foster, President and CEO of Optherion, said: "The licensing agreement with the University of Pittsburgh adds significantly to our portfolio. Optherion is now in position to develop diagnostic tests based upon the most recently discovered genetic associations of dry AMD.

"We are optimistic that the innovative discoveries we are licensing will lead to diagnostic tests that can help change the current paradigm of AMD risk assessment and patient care," Mr. Foster added.

The finding that genetic variations on Chromosome 10 are implicated in AMD was published in the American Journal of Human Genetics by scientists from the University of Pittsburgh under the direction of Dr. Michael B. Gorin, an ophthalmologist whose career has been dedicated to studying the molecular genetics of hereditary eye diseases ("Susceptibility Genes for Age-Related Maculopathy on Chromosome 10q26," Johanna Jakobsdottir, Yvette P. Conley, Daniel E. Weeks, Tammy S. Mah, Robert E. Ferrell, and Michael B. Gorin (Am. J. Hum. Genet. 77:389-407, 2005)). Dr. Gorin in September 2006 became Professor of Ophthalmology and Harold and Pauline Price Chair in Ophthalmology at the Jules Stein Eye Institute at UCLA in Los Angeles.

Publications by other researchers have substantiated and replicated the links of CFH, CFB and Chromosome 10 to AMD. Additional research published in 2007 found that people with homozygous risk profiles for CFH, CFB and LOC387715/HTRA1 have as great as a 250 times increased risk of developing AMD.

About Optherion:

Optherion, Inc. is an early-stage biotechnology company that is developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on recent scientific discoveries linking certain genes to AMD. Optherion has offices and laboratories in New Haven, CT., and on the biotechnology campus of the University of Iowa in Coralville, IA.


'/>"/>
SOURCE Optherion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Drop in Worldwide Measles deaths by 40%
9. Drugs Banned worldwide still available in India
10. Domestic Violence: The Silent Killer of Women Worldwide
11. New Study Questions Cannibalism As A Worldwide Selective Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
Breaking Medicine Technology: